Minerva Ebitda from 2010 to 2024

NERV Stock  USD 2.26  0.00  0.00%   
Minerva Neurosciences EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -22.8 M in 2024. During the period from 2010 to 2024, Minerva Neurosciences EBITDA regression line of quarterly data had mean square error of 537.3 T and geometric mean of  13,647,964. View All Fundamentals
 
EBITDA  
First Reported
2013-03-31
Previous Quarter
-5.9 M
Current Value
22.5 M
Quarterly Volatility
9.5 M
 
Yuan Drop
 
Covid
Check Minerva Neurosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Minerva Neurosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 29.4 K, Interest Expense of 8.7 M or Selling General Administrative of 10.9 B, as well as many indicators such as Price To Sales Ratio of 1.86, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Minerva financial statements analysis is a perfect complement when working with Minerva Neurosciences Valuation or Volatility modules.
  
Check out the analysis of Minerva Neurosciences Correlation against competitors.
For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.

Latest Minerva Neurosciences' Ebitda Growth Pattern

Below is the plot of the Ebitda of Minerva Neurosciences over the last few years. It is Minerva Neurosciences' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Minerva Neurosciences' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Minerva Ebitda Regression Statistics

Arithmetic Mean(27,106,311)
Geometric Mean13,647,964
Coefficient Of Variation(88.10)
Mean Deviation19,028,783
Median(24,693,607)
Standard Deviation23,881,123
Sample Variance570.3T
Range77.8M
R-Value(0.35)
Mean Square Error537.3T
R-Squared0.13
Significance0.20
Slope(1,889,686)
Total Sum of Squares7984.3T

Minerva Ebitda History

2024-22.8 M
2023-21.7 M
2022-24.7 M
2021-51.6 M
20201.9 M
2019-75.9 M
2018-51.7 M

About Minerva Neurosciences Financial Statements

Minerva Neurosciences investors use historical fundamental indicators, such as Minerva Neurosciences' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Minerva Neurosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-21.7 M-22.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Minerva Stock Analysis

When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.